Silk Road Medical, Inc Stock

Equities

SILK

US82710M1009

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-05-31 pm EDT 5-day change 1st Jan Change
21.74 USD +5.64% Intraday chart for Silk Road Medical, Inc -0.87% +77.18%
Sales 2024 * 197M Sales 2025 * 218M Capitalization 858M
Net income 2024 * -54M Net income 2025 * -52M EV / Sales 2024 * 4.29 x
Net cash position 2024 * 11.13M Net cash position 2025 * 41.33M EV / Sales 2025 * 3.74 x
P/E ratio 2024 *
-15.9 x
P/E ratio 2025 *
-16.6 x
Employees 474
Yield 2024 *
0.58%
Yield 2025 *
-
Free-Float 95.74%
More Fundamentals * Assessed data
Dynamic Chart
1 day+5.64%
1 week-0.87%
1 month+11.83%
3 months+20.84%
6 months+133.01%
Current year+77.18%
More quotes
1 week
20.53
Extreme 20.53
22.30
1 month
18.84
Extreme 18.84
22.89
Current year
11.05
Extreme 11.05
22.89
1 year
6.08
Extreme 6.08
34.13
3 years
6.08
Extreme 6.08
67.49
5 years
6.08
Extreme 6.08
75.80
10 years
6.08
Extreme 6.08
75.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 Nov. 01
Director of Finance/CFO 46 09-07-31
Chief Tech/Sci/R&D Officer - 20-09-20
Members of the board TitleAgeSince
Director/Board Member 56 18-03-25
Director/Board Member 51 20-12-02
Chairman 71 07-03-31
More insiders
Date Price Change Volume
24-05-31 21.74 +5.64% 1,959,115
24-05-30 20.58 -3.24% 633,633
24-05-29 21.27 -0.37% 504,439
24-05-28 21.35 -2.64% 683,269
24-05-24 21.93 +1.86% 385,326

Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT

More quotes
Silk Road Medical, Inc. is a medical device company that is focused on reducing the risk of stroke and its impact. The Company has developed an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. Its product portfolio consists of five single-use components: ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014'' Guidewire and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. It manufactures ENROUTE NPS and ENROUTE NPS PLUS, or its ENROUTE NPS products, at its facilities in Sunnyvale, California and Plymouth, Minnesota. These facilities provide an aggregate of over 35,000 square feet of space for its production and distribution operations.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
21.74 USD
Average target price
19 USD
Spread / Average Target
-12.60%
Consensus